Who Paid My Doc
Marcus Ortega
Obstetrics & Gynecology Boston, MA Medical Doctor
NPI 1205275385 CMS profile 9523
55 Fruit St, Yawkey 4E, Boston, MA 02114
General payments
$17,263
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Marcus Ortega of Boston, MA is reported in the CMS Open Payments database as having received $17,263 across 71 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,822 | 27 | |
| 2024 | General | $1,880 | 6 | |
| 2023 | General | $3,459 | 15 | |
| 2022 | General | $8,286 | 12 | |
| 2021 | General | $445 | 6 | |
| 2020 | General | $59 | 1 | |
| 2019 | General | $312 | 4 |
Beside peers
- Marcus Ortega
- Obstetrics & Gynecology median
- Middle half of Obstetrics & Gynecology
- National median
In program year 2025, general payments to Marcus Ortega were reported at $2,822. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.
Show as a table
| Year | Marcus Ortega | Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $312 | $172 | $62–$391 | $163 |
| 2020 | $59 | $94 | $36–$222 | $114 |
| 2021 | $445 | $136 | $42–$369 | $132 |
| 2022 | $8,286 | $160 | $50–$433 | $149 |
| 2023 | $3,459 | $169 | $56–$423 | $160 |
| 2024 | $1,880 | $152 | $50–$371 | $164 |
| 2025 | $2,822 | $158 | $51–$401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
639
Drug cost
$188,270
Branded share of claims
56%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 160 | $110,508 | |
| Myrbetriq Mirabegron | Brand | 107 | $52,542 | |
| Estradiol | Generic | 161 | $12,988 | |
| Mirabegron Er Mirabegron | Brand | 12 | $5,200 | |
| Yuvafem Estradiol | Brand | 21 | $4,011 | |
| Methenamine Hippurate | Generic | 38 | $2,553 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 28 | $252 | |
| Ibuprofen | Generic | 22 | $67 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 30 | $61 | |
| Ciprofloxacin Hcl | Generic | 25 | $49 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$181,921
Medicare patients
357
Services billed
6,136
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 67% | |
| Arthritis | 56% | |
| Osteoporosis | 32% | |
| Depression | 29% | |
| Chronic kidney disease | 20% | |
| Cancer | 20% | |
| Ischemic heart disease | 18% | |
| Diabetes | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 26 | 4,400 | $21,912 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
71 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obstetrics & Gynecology in Massachusetts
Soheil Amin Hanjani
Obstetrics & Gynecology · Brockton, MA
Joelle Lieman
Obstetrics & Gynecology · Brighton, MA
Elizabeth Onyemelukwe
Obstetrics & Gynecology · Boston, MA
James Greenberg
Obstetrics & Gynecology · Boston, MA
Stephanie Alimena
Obstetrics & Gynecology · Boston, MA
Denis Vaughan
Obstetrics & Gynecology · Boston, MA
Related records
Obstetrics & Gynecology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.